[Obsidan treatment of neuroendocrine disorders and hyperkinetic syndrome in patients with macrofocal myocardial infarction].
The trend in blood plasma adrenaline, noradrenaline, renin and parameters of central hemodynamics were studied in randomized sample of 67 patients with uncomplicated macrofocal myocardial infarction with a hyperkinetic syndrome. To 32 patients obsidan was administered intravenously (0.1 mg/kg), then orally for 2-3 days every 3-4 hours to lessen cardiac contraction rate by 20-30 per cent and to obtain moderate hypotension and after than 60-120 mg per 24 hours. The traditional treatment was prescribed to 35 patients of the control group. The acute period of the disease was marked by increased concentrations of catecholamines and renin and a close correlation between them and the central hemodynamic parameters. Use of obsidan led to a more rapid reduction and normalization of the content of biologically active substances, central hemodynamic parameters and to the removal of their correlation. The mechanisms of obsidan action are discussed.
Simerzin
V V
VV
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004837:Epinephrine / Q000097:blood*; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D009449:Neurocirculatory Asthenia / Q000188:drug therapy*; D009638:Norepinephrine / Q000097:blood*; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D012083:Renin / Q000097:blood*; D012084:Renin-Angiotensin System; D013564:Sympathetic Nervous System / Q000503:physiopathology
D011433:Propranolol; D012083:Renin; D009638:Norepinephrine; D004837:Epinephrine
Korrektsiia obzidanom neĭroéndokrinnykh narusheniĭ i giperkineticheskogo sindroma u bol'nykh krupnoochagovym infarktom miokarda.